14 October 2025
Fuse Vectors presents in Manchester
We were excited to take part in this year’s BioProNET2 Science Symposium in Manchester, where our Co-Founder and Co-CEO Jordan Turnbull gave a talk on “Cell-Free Innovation: Better and Faster Viral Vectors for All.”
His presentation highlighted how our cell-free enzymatic platform is helping to overcome key manufacturing bottlenecks in AAV development, making vector production faster, higher in quality, and easier to scale.
Read more about the event here
24 September 2025
Fuse Vectors graduates from the
BII Venture House program
Fuse Vectors has officially graduated from the BioInnovation Institute (BII) Venture House program, marking an important milestone in the company’s growth journey.
The Venture House program has served as a launchpad for Fuse Vectors’ development, supported by the dedication of its team and the strong network within the BII community.
Looking ahead, we are continuing our path within the BII Residence program, scaling our vision to transform AAV development and gene therapy manufacturing.
Read more here:
15 September 2025
Fuse Vectors at ESGCT 2025
We’re thrilled to share that our co-founders Jordan Turnbull and Benjamin Blaha were invited by Cytiva to speak at the European Society of Gene & Cell Therapy (ESGCT) 2025 conference in Seville, Spain.
Their session, “Advanced therapies at the crossroads: where process excellence meets innovation,” highlighted how Fuse Vectors’ cell-free manufacturing platform is redefining AAV gene therapy with higher quality, faster timelines, and built-in scalability.
A big thank you to Cytiva for the invitation and for bringing together such an inspiring community of innovators in advanced therapies.
19 August 2025
Fuse Vectors Presents at NBC 2025
We are proud to share that our Co-founder Benjamin Blaha will speak at the Netherlands Biotechnology Congress (NBC 2025) in Wageningen this September. Benjamin will present Fusevectors pioneering work on cell free manufacturing of viral vector gene therapies.
Stay tuned for more! For details, check out our LinkedIn post here.
25 February 2025
Fuse Vectors secures 5.2m USD in pre-seed funding to advance cell-free gene therapy technology led by HCVC
Fuse Vectors has closed a successful pre-seed financing round led by HCVC to accelerate its cell-free AAV technology to revolutionize gene therapy with scalable, high-quality viral vector development. This funding, alongside early support from BioInnovation Institute, EIFO and Innovation Fund, enables the advancement of the technology, development of innovative gene therapies and forging of strategic partnerships with pharma, biotech and academia.
Read the full coverage on Forbes here.
4 November 2024
Fuse Vectors wins grand prize in Merck's 2024 EMEA Advanced Biotech Grant
We are thrilled that Fuse Vectors has won the Merck's EMEA Advanced Biotech Grant! This prestigious recognition, announced on the first day of Bio-Europe, highlights our innovative approach and dedication to advancing biotechnology. We extend our heartfelt thanks to Merck Life Science for this honor and for organizing the grant and Bio-Europe. For more details, check out our LinkedIn post below!
10 October 2024
Fuse Vectors: Our journey since stealth
Since emerging from stealth mode, Fuse Vectors has achieved several thrilling milestones. From joining the prestigious NOME Mentoring Network to presenting at key industry events and being selected as a finalist for the Merck Advanced Biotech Grant, our journey has been nothing short of remarkable.
We invite you to read more about our recent achievements and see some memorable moments on our LinkedIn post here.
29 January 2024
Fuse Vectors emerges from stealth at BII's Demo Day 2024
We are thrilled to announce our emergence from stealth mode at the BioInnovation Institute's Demo Day, where we unveiled our groundbreaking gene therapy AAV development platform.
Special thanks to the companies which have supported us through this journey, and to our incredible team for making this possible.
Stay tuned for more! For details, check out our LinkedIn post here.